Can We Talk? US FDA Remote Records Review Missteps Worry Industry
Executive Summary
Alkermes CRL is just the latest fallout from black-hole process.
You may also be interested in...
Alkermes CEO Appeals To US FDA’s Woodcock In ‘COVID-19 Pandemic And Depression’ Meeting
Richard Pops has publicly complained about the agency’s review performance during COVID, and Alkermes’ application for a mental health product appears to have been held up because of inspection issues.
Pandemic Taking Its Toll On The US FDA’s Non-Pandemic Work, Alkermes CEO Says
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.